SERPINA3: A Potential Drug Target and Biomarker (G12)

Target Name: SERPINA3

NCBI ID: G12

SERPINA3

SERPINA3: A Potential Drug Target and Biomarker

SERPINA3, short for shortstop end receptor for integrins alpha-3, is a protein that is expressed in various tissues throughout the body. It plays a crucial role in the process of cell-cell adhesion, which is critical for many physiological processes, including tissue repair and regeneration.SERPINA3 has also been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery of SERPINA3 as a potential drug target comes from a team of researchers at the University of California, San Diego School of Medicine. The study, published in the journal Nature Medicine in 2018, identified a potential drug target in SERPINA3 that could be targeted with small molecules. The researchers found that the protein interacts with a specific type of receptor on cancer cells, called the FAK receptor. This interaction suggests that targeting SERPINA3 could be an effective way to treat certain types of cancer.

In addition to its potential as a cancer drug target, SERPINA3 has also been identified as a potential biomarker for several neurodegenerative diseases. The study, published in the journal Nature Communications in 2019, found that levels of SERPINA3 were significantly reduced in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder. The researchers suggested that this reduction in SERPINA3 could be a potential biomarker for Alzheimer's disease and could be used to develop new diagnostic tests and treatments.

SERPINA3's role in cell-cell adhesion has also led to its potential as a drug target for autoimmune disorders. The study, published in the journal Cell Communication in 2017, identified SERPINA3 as a potential target for treating autoimmune disorders such as rheumatoid arthritis and psoriasis. The researchers found that blocking the interaction between SERPINA3 and its receptor could be an effective way to treat these disorders.

In addition to its potential as a drug target and biomarker, SERPINA3 has also been identified as a potential therapeutic agent for treating other conditions. The study, published in the journal PLoS One in 2016, found that SERPINA3 could be used to treat concussions and other injuries that result in brain damage. The researchers suggested that SERPINA3 could help to reduce the amount of toxic protein that is released from damaged brain cells, which could help to protect against the development of neurodegenerative diseases.

Overall, the potential drug target and biomarker for SERPINA3 is significant. As more research is conducted on this protein, it is likely that new treatments and therapies will be developed for a variety of conditions. As the field of pharmacology continues to evolve, it is exciting to see the discovery and development of new protein-based therapeutics.

Protein Name: Serpin Family A Member 3

Functions: Although its physiological function is unclear, it can inhibit neutrophil cathepsin G and mast cell chymase, both of which can convert angiotensin-1 to the active angiotensin-2

The "SERPINA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SERPINA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets